Key takes from BioTrinity 2026 ddw-online.com/key-takes-fro… Follow DDW; Business insights for the global scientific community #BioTrinity2026

🧬 A special #MarketClose in partnership with OBN, bringing together life sciences R&D leaders and investors ahead of the 20th edition of BioTrinity. 🔗: lseg.group/482gtwB #LifeSciences #RAndD #BioTrinity

𝐔𝐊 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬: BiotechTV's @ByAmyBrown caught up with Stuart Rose of OBN (UK), which is now BioUK, today at BioTrinity 2026.

Our Head of BD, Carl Curran, had a great day at #BioTrinity earlier this month— full of high-quality partnering meetings and strong interest in our best-in-class anti-infectives. A big thanks to all who connected! #AntiInfectives #LifeSciences

I had the privilege of presenting at the #BioTrinity25 conference on the ubiquitous problem of #necrosis and how our Anti-Necrotic™ is filling a critical #therapeutic gap. @OBN_UK It was an exciting opportunity to share insights into how this innovative solution could significantly impact patient outcomes- particularly in #chronic #disease and loss of #resilience with #age. #BioTrinity #Innovation #LifeSciences #Therapeutics #Necrosis

Our CEO speaks with @VOXmarkets at @TheBDC during the @masterinvestor Show on Saturday. 🤝 Attending Master Investor 🎤 #BIOTrinity conference ✅ Partnering Oral GLP1 & POLB 001 🔑 Key message to investors Watch full interview: youtube.com/watch?v=oIHJRk7k… #POLB #MasterInvestor #BusinessDesignCentre #London #AIM #Pharma

𝐁𝐢𝐨𝐓𝐫𝐢𝐧𝐢𝐭𝐲 𝟐𝟎𝟐𝟓: With a novel E3 ubiquitin ligase (TRIM21) for protein degradation, Cambridge, UK based TRIMTECH Therapeutics recently raised a $31 million seed round. Full video: biotechtv.com/post/trimtech-…

A reminder that Our Chief Executive Officer will be presenting our exciting POLB 001 data & Oral GLP1 agonist today at @OBN_UK's #BioTrinity in London. 👉 Session: Science Spotlight 8 - Rare Disease Meet Jeremy there to learn more about our programmes. Learn more: obn.glueup.com/event/biotrin… #POLB #BioTrinity #London

𝐁𝐢𝐨𝐓𝐫𝐢𝐧𝐢𝐭𝐲 𝟐𝟎𝟐𝟓: AlveoGene Executive Chair David Hipkiss describes the company's unique inhaled gene therapy platform that fuses a Sendai virus and Lentivirus, and can be redosed. Full video: biotechtv.com/post/alveogene…

This morning at @OBN_UK's #BioTrinity event in London - our CEO @gino_prof is live now on the first panel "An insight into the macro environmental factors impacting your business" 📸 @uob_be

Infex Therapeutics is attending #BioTrinity tomorrow & Wednesday in London, hosted by @OBN_UK . If you wish to meet with us, please send a meeting request via the partnering app. Find out more at biotrinity.com

#POLB @PoolbegPharma - Conference Participation in March & April 2025 -CEO, Jeremy Skillington, will be speaking at top industry events. -Master Investor Show – 29/03, 1PM -BioTrinity – 02/04, 9:30AM -LSX World Congress – 30/04, 2PM novuscomms.com/2025/03/27/po…

We will be participating in three key Conferences in March and April 2025: ✅@masterinvestor - Saturday 29 March ✅@OBN_UK's #BioTrinity - Wednesday 2 April ✅@LSXLeaders World Congress - Wednesday 30 April Meet us there to learn more about the development of Poolbeg's innovative medicines to address unmet medical needs. Learn more: londonstockexchange.com/news… #POLB #Conferences #MasterInvestor25 #BioTrinity #LSXConference

Attending BioTrinity (@OBN_UK) next week? Join @labgeni_us' CEO, James Field, for his Science Spotlight presentation describing how our unique discovery platform is being used to establish a wholly-owned pipeline of highly selective T-cell engagers for the treatment of solid tumours. LabGenius’ platform, which is underpinned by the closed-loop integration of ML and high-throughput experimentation, enables the rapid identification and co-optimisation of complex multispecific antibodies across multiple key properties, including killing selectivity, potency and developability. Find the full conference agenda here: lnkd.in/eET2n7cR To learn more about LabGenius’ cutting-edge platform and therapeutic pipeline, please email us at partnerships@labgeni.us

Our Chief Executive Officer will be presenting Poolbeg Pharma, our exciting drug candidate POLB 001, an oral preventative therapy for cancer immunotherapy-induced CRS at @biotrinity in London. 📅 Wednesday 2 April 👉 Session: Science Spotlight 8 - Rare Disease Meet Jeremy there to learn more about our high value programmes. Learn more: obn.glueup.com/event/biotrin… #POLB #BioTrinity #London

Thank you to our Double Level Sponsors this season! Bailey Orthodontics, BioTrinity Consulting, LLC, Coppell Chronicle

BioTrinity 24: A bigger and brighter future for life sciences. A Day Two Wrap-Up obn.org.uk/news/biotrinity-2…

Biotrial would like to thank everyone who attended Biotrinity hosted in London. Eric and Rob had an amazing time connecting with industry leaders, experts, and innovators from around the world. We look forward to seeing you all again soon!  #biotrinity2024

Our feet are tired but our minds are buzzing with all the inspirational content we’ve taken in over the past two days at #BioTrinity! Read our day 2 summary here: obn.org.uk/news/biotrinity-2…

An exciting end to today’s agenda was our new addition to the #BioTrinity programme for 2024, the Academic Poster Presentations. The presenters did a fantastic job of engaging the audience with speed pitches capped at a very strict 60 seconds!